Buy Retatrutide 10mg in NZ for advanced metabolic and GLP-1 peptide research.

Retatrutide

10mg
$209.00
Skip to product information
Buy Retatrutide 10mg in NZ for advanced metabolic and GLP-1 peptide research.
  • Buy Retatrutide 10mg in NZ for advanced metabolic and GLP-1 peptide research.
  • Retatrutide
  • Buy Retatrutide 10mg in NZ for advanced metabolic and GLP-1 peptide research.
  • Retatrutide
Retatrutide

Retatrutide

Retatrutide is a novel multi-agonist peptide under investigation for its role in metabolic regulation, glucose control, and weight management. It is designed to mimic and activate pathways influenced by natural hormones such as GLP-1, GIP, and glucagon, which are involved in appetite regulation, energy balance, and blood sugar homeostasis.

Scientific research has focused on Retatrutide’s potential to support studies related to obesity, insulin sensitivity, and type 2 diabetes, positioning it as a next-generation compound in the field of metabolic and endocrine research.

This peptide is available exclusively for scientific and laboratory research use in New Zealand.

Purity: ≥99.0%

Molar Mass: 4731.33

Molecular Formula: C₂₂₇H₃₅₄N₄₈O₆₉

Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

  1. Jastreboff, Ania M., et al. "Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial." New England Journal of Medicine 389.6 (2023): 514-526.
  2. Rosenstock, Julio, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet 402.10401 (2023): 529-544.
  3. Doggrell, Sheila A. "Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?." Expert opinion on investigational drugs 32.5 (2023): 355-359.
  4. Urva, Shweta, et al. "The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying." Diabetes, Obesity and Metabolism 25.9 (2023): 2784-2788.
  5. Kaur, Manmeet, and Saurav Misra. "A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity." European Journal of Clinical Pharmacology 80.5 (2024): 669-676.

Bulk Order Discounts Available

Receive 10% off when ordering 3+ vials

Receive 15% off when ordering 6+ vials
$209.00
Content

You may also like